Rocket One, Inc.

Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell Program 允许的专利权利要求涵盖针对MS4A6A前体mRNA剪接以减少高亲和力IgE受体（FcεRI）表面表达的物质组成和方法；加强了HT-KIT肥大细胞计划的知识产权基础。HOBOKEN, N.J. 霍博肯，新泽西州, ，May 26, 2026 2026年5月26日/PRNewswire/ -- /PRNewswire/ --Hoth Therapeutics, Inc. 霍斯治疗公司(NASDAQ: （纳斯达克：HOTH 霍斯) ('Hoth' or the 'Company'), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ('USPTO') has issued a ）（“霍斯”或“公司”），一家临床阶段的生物制药公司，今天宣布美国专利商标局（“USPTO”）已发布了一项Notice of Allowance 允许通知for Hoth's HT-KIT therapeutic. 霍斯的HT-KIT治疗剂。The allowed claims cover antisense oligomers of 25 to 50 linked nucleosides directed to splicing-relevant regions of the MS4A6A pre-mRNA, including intron 3, exon 4, and the intron 3/exon 4 junction, together with pharmaceutical compositions and methods for modulating MS4A6A mRNA splicing in cells or tissues. 允许的专利权利要求涵盖了针对 MS4A6A 前体 mRNA 的剪接相关区域（包括内含子 3、外显子 4 以及内含子 3/外显子 4 连接处）的 25 至 50 个连接核苷酸的反义寡聚体，同时还包括用于调节细胞或组织中 MS4A6A mRNA 剪接的药物组合物和方法。Hybridization of the disclosed oligomers is intended to reduce cell-surface expression of the high-affinity IgE receptor (FcεRI), a central driver of mast cell activation in allergic and inflammatory disease.. 所公开的寡聚物的杂交旨在减少高亲和力 IgE 受体 (FcεRI) 的细胞表面表达，该受体是过敏性和炎症性疾病中肥大细胞活化的主要驱动因素。Strategic Importance 战略重要性Foundational IP Position. 基础知识产权地位。Allowance establishes composition-of-matter coverage for the Company's lead antisense oligomer (SEQ ID NO: 22), including modified, morpholino, and pharmaceutical composition embodiments, providing a defensible basis for the underlying chemistry of the platform. 允许权的确立涵盖了公司主要的反义寡聚体（SEQ ID NO: 22）的物质组成，包括修饰的、吗啉代的以及药物组合物的实施例，为平台的底层化学提供了可防御的基础。Mechanistic Differentiation. 机制差异化。By reducing surface expression of FcεRI via exon-skipping of MS4A6A pre-mRNA, the approach addresses a node upstream of histamine release and IgE-mediated degranulation, distinct from antihistamine, anti-IgE antibody, and small-molecule mast cell inhibitor approaches. 通过跳过MS4A6A前体mRNA的外显子来减少FcεRI的表面表达，该方法针对组胺释放和IgE介导的脱颗粒上游的一个节点，不同于抗组胺药、抗IgE抗体和小分子肥大细胞抑制剂的方法。Broad Indication Coverage. 广泛的适应症覆盖。Allowed method claims and related disclosures span asthma, atopic dermatitis, chronic rhinitis, allergic conjunctivitis, chronic sinusitis, anaphylaxis prevention, and mast cell–driven diseases including mastocytosis and mast cell tumors. 允许的方法声明及相关披露涵盖哮喘、特应性皮炎、慢性鼻炎、过敏性结膜炎、慢性鼻窦炎、过敏反应预防以及肥大细胞相关疾病，包括肥大细胞增多症和肥大细胞肿瘤。Reinforces HT-KIT. 加强HT-KIT。The allowed claims strengthen the intellectual property foundation underlying HT-KIT, the Company's orphan drug–designated program for mast cell–driven disease. 允许的索赔加强了HT-KIT的知识产权基础，这是公司针对肥大细胞驱动疾病的孤儿药指定项目。Combination Optionality. 组合可选性。The application as filed also describes combination approaches with antisense oligomers targeting FcεRIβ (MS4A2) pre-mRNA splicing, supporting future development of dual-target compositions. 该申请还描述了与靶向FcεRIβ（MS4A2）前体mRNA剪接的反义寡聚体组合方法，支持未来双靶点组合物的开发。Management Commentary 管理层评论'This Notice of Allowance is a meaningful validation of the science underlying our mast cell platform and an important addition to the intellectual property foundation supporting HT-KIT,' said “该允许通知对我们肥大细胞平台背后的科学意义重大，并且是支持HT-KIT的知识产权基础的重要补充，”表示。Robb Knie 罗布·克尼, Chief Executive Officer of Hoth Therapeutics. Hoth Therapeutics的首席执行官。About HT-KIT 关于HT-KITHT-KIT is Hoth Therapeutics' orphan drug–designated program directed at mastocytosis and other mast cell–driven diseases. The program is built around antisense oligomer–mediated modulation of pre-mRNA splicing to reduce pathological mast cell signaling. Hoth expects to finalize its IND submission in 2026, followed by first-in-human studies.. HT-KIT是Hoth Therapeutics公司针对肥大细胞增多症和其他肥大细胞驱动疾病的孤儿药指定项目。该项目围绕反义寡核苷酸介导的前体mRNA剪接调节，以减少病理性肥大细胞信号传导。Hoth预计将在2026年完成其IND申请提交，并随后开展首次人体研究。Biotechnology Operations Continue Under Subsidiary Structure 子公司结构下生物技术业务继续进行The Company'sis exploring placing itsbiotechnology pipeline and therapeutic development programsunder aseparate,wholly ownedsubsidiary with dedicated management and operational resources.The restructuring is intended to preserve the value of the biotechnology portfolio for shareholders while enabling the parent company to pursue emerging opportunities in AI semiconductor infrastructure and advanced computing technologies.. 公司正在探索将其生物技术管线和治疗开发项目置于一家独立的全资子公司之下，该子公司将拥有专门的管理和运营资源。此次重组旨在为股东保留生物技术组合的价值，同时使母公司能够追求人工智能半导体基础设施和先进计算技术领域的新兴机会。About Rocket One, Inc. 关于火箭一号公司Rocket One Inc. is focused on the development and commercialization of spintronic computing technologies for artificial intelligence hardware acceleration and radiation-tolerant computing applications. The Company holds exclusive rights to technologies licensed for nanomagnetic matrix multiplier architecture designed as a hardware accelerator for machine learning and artificial intelligence workloads, and a skyrmion-based spintronic memory technology with potential applications in radiation-tolerant computing for defense and space systems.. 火箭一号公司专注于开发和商业化用于人工智能硬件加速和抗辐射计算应用的自旋电子计算技术。公司拥有独家授权的技术，包括用于机器学习和人工智能工作负载的纳米磁矩阵乘法器架构的硬件加速器，以及基于斯格明子的自旋电子存储技术，该技术在国防和航天系统的抗辐射计算中具有潜在应用。About Hoth Therapeutics, Inc. 关于霍斯治疗公司Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Hoth Therapeutics是一家临床阶段的生物制药公司，致力于开发创新、有影响力且突破性的治疗方法，旨在改善患者的生活质量。我们是早期药物研发的推动者，将药物从实验室提升至临床前和临床测试阶段。Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit . 采用以患者为中心的方法，我们与科学家、临床医生和关键意见领袖团队合作，寻找并研究具有巨大潜力的治疗方法，以实现突破并多样化治疗选择。欲了解更多信息，请访问 。https://ir.hoththerapeutics.com/ https://ir.hoththerapeutics.com/. 。Forward-Looking Statement 前瞻性声明Thispressrelease includesforward-lookingstatementsbaseduponHoth's currentexpectations,whichmay constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. 本新闻稿包含基于Hoth当前预期的前瞻性声明，这些声明可能构成1995年《私人证券诉讼改革法案》及其他联邦证券法规定的安全港条款下的前瞻性声明，并受重大风险、不确定性和假设的影响。These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidatesandanyotherproduct candidateswemaydevelop,andthelabeling underanyapproval wemay obtain;thetimingandcostsofclinicaltrials, andthetiming andcostsofotherexpenses;marketacceptance ofourproducts;theultimateimpact ofthecurrentcoronaviruspandemic, oranyotherhealthepidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. 这些声明涉及霍斯的商业策略；监管提交的时间；获得并维持现有产品候选物及我们可能开发的任何其他产品候选物的监管批准的能力，以及我们可能获得的任何批准下的标签；临床试验的时间和成本，以及其他费用的时间和成本；市场对我们产品的接受程度；当前冠状病毒大流行或任何其他健康流行病对我们业务、临床试验、研究计划、医疗系统或整体全球经济的最终影响；我们的知识产权；我们对第三方组织的依赖；我们的竞争地位；我们的行业环境；我们预期的财务和运营结果，包括预期的收入来源；我们关于可用市场规模、产品优势、产品定价和产品上市时间的假设；管理层对未来收购的预期；关于我们目标、意图、计划和期望的声明，包括新产品的引入和市场开拓；以及我们的现金需求和融资计划。There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as 'could,' 'believe,' 'anticipate,' 'in. 有许多因素可能导致实际事件与这些前瞻性陈述所表明的情况有重大差异。你不应过分依赖这些包含诸如“可能”、“相信”、“预期”、“在”等词汇的前瞻性陈述。Investor Contact: 投资者联系人： LR Advisors LLC LR顾问有限责任公司Email: 电子邮件：[emailprotected] 电子邮件地址www.hoththerapeutics.com www.hoththerapeutics.comPhone:(678) 570-6791 电话：（678）570-6791SOURCE Hoth Therapeutics, Inc. 来源：Hoth Therapeutics, Inc.21 21% %more press release views with 更多新闻发布视图与 Request a Demo 请求演示

Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions May 5, 2026 -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced that it has secured regulatory authorization in Spain for its Phase 2a CLEER Trial of HT-001, while concurrently reporting encouraging interim clinical results demonstrating meaningful efficacy and safety in cancer patients experiencing EGFR inhibitor-associated skin toxicities. The authorization supports the continued advancement of Hoth's randomized, placebo-controlled, dose-ranging Phase 2a study evaluating HT-001 for the treatment of dermatologic toxicities associated with epidermal growth factor receptor (EGFR) inhibitor therapies. Preliminary data from the ongoing study indicate: Patients achieved the primary efficacy endpoint, with rash severity reduced to clinically manageable levels (ARIGA ≤1) by Week 6 Over 65% of patients reported meaningful reductions in pain and itching Zero patients required dose reduction or discontinuation of their underlying EGFR inhibitor cancer therapy Favorable safety profile, with no treatment-limiting adverse events observed These findings suggest that HT-001 may enable patients to remain on life-saving cancer therapies longer, addressing a major limitation of current oncology treatment regimens. "Regulatory advancement paired with strong clinical signals has helped open up a new avenue for patients in Spain," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "Securing European authorization while demonstrating meaningful patient benefit reinforces our belief that HT-001 has the potential to become a critical supportive care therapy in oncology." The Spain authorization marks an important step in Hoth's European strategy and supports continued trial execution and expansion across additional regions. The CLEER Trial (Chemotherapy Longevity by Evading EGFR Inhibitor Reactions) is a Phase 2a randomized, placebo-controlled, parallel, dose-ranging study evaluating HT-001 in patients experiencing EGFR inhibitor-related dermatologic toxicities. HT-001 is a novel topical therapeutic designed to target inflammatory pathways associated with cancer therapy-induced skin toxicities, with the goal of improving tolerability and enabling uninterrupted treatment. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. The content above comes from the network. if any infringement, please contact us to modify.

Hoth Therapeutics reported interim Phase IIa results for HT-001 in cancer patients experiencing EGFR inhibitor-associated dermatologic toxicities, according to a May 5, 2026 press release, which also announced regulatory authorization in Spain to expand the ongoing CLEER trial. The New York-based company said patients achieved the primary efficacy endpoint, with rash severity reduced to clinically manageable levels, defined as an ARIGA score of 1 or below, by Week 6. The CLEER trial is a randomized, placebo-controlled, parallel, dose-ranging Phase IIa study evaluating HT-001 in patients with EGFR inhibitor-related dermatologic toxicities. According to interim data reported by the company, more than 65% of patients reported reductions in pain and itching, and no patients required dose reduction or discontinuation of their underlying EGFR inhibitor cancer therapy. Hoth also stated that no treatment-limiting adverse events were observed. The number of patients included in this interim analysis was not disclosed, nor were dosing details or Data Safety Monitoring Board oversight information. The trial, registered under CTIS2025-523058-16-00, is enrolling patients across the United States, Hungary, and Spain, with the Spanish authorization announced concurrently with the interim readout. The data are interim and drawn from an unspecified subset of enrolled patients; full enrollment figures and unblinded comparative data between active and placebo arms were not reported. The interim nature of the dataset and the absence of patient-level or statistical detail limit interpretation of the findings at this stage. HT-001 is a topical gel formulated with a neurokinin-1 receptor antagonist, targeting Substance P-mediated neuroinflammatory signaling implicated in EGFR inhibitor-associated skin toxicity. No established standard-of-care topical therapy has regulatory approval specifically for this indication, though tetracycline-class antibiotics and topical corticosteroids are used in clinical practice. Cross-trial comparisons are limited by differences in study design, duration, and patient populations. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website